Last month, the country’s second-largest drug maker had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
